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Abstract
Background: Common mental disorders are the most prevalent of all mental disorders, with the highest
burden in terms of work absenteeism and utilization of health care services. Evidence-based treatments
are available, but recognition and treatment could be improved, especially in the occupational health
setting. The situation in this setting has recently changed in the Netherlands because of new legislation,
which has resulted in reduced sickness absence. Severe mental disorder has now become one of the main
causes of work absenteeism. Occupational physicians (OPs) are expected to take an active role in diagnosis
and treatment, and seem to be in need of support for a new approach to handle cases of more complex
mental disorders. Psychiatric consultation can be a collaborative care model to achieve this.
Methods/design: This is a two-armed cluster-randomized clinical trial, with randomization among OPs.
Forty OPs in two big companies providing medical care for multiple companies will be randomized to
either the intervention group, i.e. psychiatric consultation embedded in a training programme, or the
control group, i.e. only training aimed at recognition and providing Care As Usual. 60 patients will be
included who have been absent from work for 6–52 weeks and who, after screening and a MINI interview,
are diagnosed with depressive disorder, anxiety disorder or somatoform disorder based on DSM-IV
criteria. Baseline measurements and follow up measurements (at 3 months and 6 months) will be assessed
with questionnaires and an interview. The primary outcome measure is level of general functioning
according to the SF-20. Secondary measures are severity of the mental disorder according to the PHQ
and the SCL-90, quality of life (EQ-D5), measures of Return To Work and cost-effectiveness of the
treatment assessed with the TiC-P. Process measures will be adherence to the treatment plan and
assessment of the treatment provided by the Psychiatric Consultant (PC) in both groups.
Discussion: In the current study, a psychiatric consultation model that has already proved to be effective
in the primary care setting, and aimed to enhance evidence-based care for patients with work absenteeism
and common mental disorder will be evaluated for its efficacy and cost-effectiveness in the occupational
health setting.
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Background
Common mental disorders, i.e. depressive disorder, anxi-
ety disorder and somatoform disorder, are the most prev-
alent of all mental disorders, with the highest burden in
terms of work absenteeism and utilization of health care
services [1-3]. In the case of depressive disorder, 80% of
the costs are due to production loss [4]. People with major
depressive disorder are absent from work 8 to 9 times as
often as people without this disorder[5,6]. Mental prob-
lems account for 30% of disability leave, and in the major-
ity of cases the employees have never been diagnosed or
treated by a psychiatrist[7]. Complaints of the muscu-
loskeletal system account for another 40%, and are con-
sidered to be possibly unrecognized somatoform,
depressive and anxiety disorder[8]. Anxiety disorders such
as generalized anxiety disorder and panic disorder, are
also highly prevalent, and have a high societal impact[9].
Moreover, on average, absence from work due to mental
disorders has a longer duration than absence caused by
physical illness[10,11].
Guidelines for evidence-based treatments are available for
depressive disorder, anxiety disorder and somatoform dis-
order[12-15,30]. However, for patients with these disor-
ders in the primary care setting there is an inadequate
offer of diagnostic and therapeutic help[16]. They often
do not receive treatment, and present in the primary care
setting with medically unexplained symptoms, thus bur-
dening the General Practitioner (GP) and the health care
setting in general with numerous visits and referrals to
medical specialists[17-20]. The GP is misdirected by the
combination of the patient's presentation with these
symptoms and the fact that he has to meet competing
demands in his practice[21]. If a mental disorder is recog-
nized, the feasibility of these guidelines appears to be low,
because many GPs feel incapable of delivering the cogni-
tive behavioural interventions described in the guidelines,
and also because of frequent care avoidance by the
patients[22,23]. Therefore, care as usual (CAU) often
implies fragmented patient-led care that is not cost-effi-
cient, including referral to medical specialists to exclude
somatic disease. This is a pity, because most of these
patients can be treated effectively[24-27] in the primary
care setting, if recognition and treatment is enhanced.
In the occupational health setting, that can be considered
to have similar characteristics in terms of prevalence, diag-
nosis and treatment of mental disorders, as the primary
care setting, a similar situation exists, but less attention
has been paid to the diagnosis and treatment of common
mental disorders. Guidelines for mental disorders in occu-
pational health have been developed by the Dutch Asso-
ciation for Occupational Health (NVAB): guidelines for
mental complaints[28], and, supplementary to the multi-
disciplinary guidelines for the diagnosis and treatment of
depression[29], a module for depression and work.
Guidelines have also been developed for the treatment of
somatoform disorder in the occupational setting[30]. The
NVAB guidelines for mental complaints[28] focus on
stress and adjustment disorders in relation to the process
of returning to work, functioning and the treatment of
work-related problems. However, adequate recognition,
treatment and criteria for the referral of patients for spe-
cialist treatment of mental disorders are not an important
part of the guideline.
The implementation of the NVAB guidelines so far has led
to a reduction in minor mental problems and in short-
term work absenteeism. However, the amount of mental
problems leading to disability leave remains high, indicat-
ing that occupational physicians (OPs) are still not accus-
tomed to the diagnosis and treatment of mental disorders.
In the Dutch legislation, responsibility for medical treat-
ment is separated from responsibility for guidance in sick-
ness absence and return to work (RTW). Only recently the
OPs in the Netherlands have been enabled by law to refer
employees to curative medical specialists if such treatment
for a present mental disorder is needed for good function-
ing or RTW. Very little research has yet focussed on inter-
ventions for patients with common mental disorders,
specifically aimed at RTW[3,31]. For many years it was
assumed that recovery from symptoms would automati-
cally lead to a recovery of functioning at work. However,
it appears that focussing on functioning in the work set-
ting contributes to a faster and a more lasting RTW in
patients with mental disorders[32]. Thus, treatment of
common mental disorder should not only focus on symp-
toms, but also on work-related functioning. This implies
a broadening of the focus from the individual patient to
the patient and the work context. Recovery should there-
fore also include the work setting: patients resume their
work as soon as possible and are supported in this by their
therapist [24]. For example, in a study carried out by Van
der Klink et al. [25] among patients with adjustment dis-
orders, in which the intervention was provided by OPs,
the intervention had a shorter duration of sick leave than
the control group. Therefore, in the present study we try to
deal with sickness absence by embedding the treatment in
the occupational setting and by including an intervention
provided by the OP, after a consultation with a psychia-
trist. Stimulating patients in RTW requires an active
approach that encompasses specific interventions tailored
to the needs created by the specific common mental dis-
order that the patient suffers from.
To summarize, in the present study design the following
elements are central: training of OPs in the diagnosis and
treatment of employees with depressive disorder, anxiety
disorder or somatoform disorder; supportive psychiatric
consultation aimed at the formulation of a diagnosis andBMC Health Services Research 2007, 7:29 http://www.biomedcentral.com/1472-6963/7/29
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a treatment plan, including suggestions for RTW adapted
to the specific needs of the patients due to their specific
disorder; and training of the consultant psychiatrists to
provide not only a diagnosis and a treatment plan, but
also to provide suggestions for successful strategies aimed
at the improvement of work functioning.
Methods/Design
Objectives
The primary aim of the present study is to test the effec-
tiveness of psychiatric consultation embedded in a train-
ing program for OPs, aimed at the diagnosis and
treatment of common mental disorders in employees
who are on sick leave, with a focus on work functioning.
The secondary aim is to estimate the cost-effectiveness of
the intervention.
Hypothesis
In a randomized controlled study comparing psychiatric
consultation with CAU provided by the OP, patients in
the intervention group will improve in terms of general
functioning, RTW, severity of the mental disorder and
quality of life.
Study design
The study is a two-armed cluster-randomized pragmatic
clinical trial with randomization among the OPs. This
intervention cannot be blinded, so the OPs might also use
the techniques that they learned in the intervention to
treat control patients. Randomization among OPs elimi-
nates the danger of such contamination, and thus dilution
of the effect. The outcome parameters will be measured by
a blinded research assistant. This procedure has already
been reported in detail elsewhere[33].
Recruitment of OPs and consultant psychiatrists
The study has been designed and will be carried out in co-
operation with ArboNed, and Arbounie, two companies
providing company medical care. Together they cover
almost half of the working population in the Netherlands.
Within these two companies, 40 OPs from four offices in
two regions will be recruited. Four consultant psychiatrists
will also be recruited.
Recruitment of patients
The aim is to include employees who have been absent
from work for a minimum of 6 weeks and a maximum of
52 weeks, do not plan to resume work within the coming
6 weeks, and have been screened on either the Patient
Health Questionnaire (PHQ) or the Whitely Index.
All patients who visited an OP within the past 6 months
will be selected from the medical files, and will receive a
letter describing the purpose of the study, together with an
informed consent form for the screening procedure and
the baseline questionnaires. Patients visiting an OP dur-
ing the inclusion period will also be invited to participate
in the study. They will also receive the informed consent
form, together with the baseline questionnaires.
Patients will be included if they reach a cut off score of
>15 on the PHQ9[34] or > 3.5 on the Whitely Index[35]
and have given informed consent for participation in the
study. The Mini-International Neuropsychiatric Interview
(MINI.)[36,37] will be administered for the classification
of symptoms according to DSM-IV[38]. In the interven-
tion group, the patients selected in this way will have a
consultation with a psychiatrist in addition to the treat-
ment provided by the OP; in the control group the
patients receive CAU provided by their OP.
Exclusion criteria
Patients will be excluded from the study if they are sui-
cidal, psychotic or suffering from dementia, have insuffi-
cient knowledge of the Dutch language to fill in the
questionnaires, or are addicted to drugs or alcohol.
Patients who are already receiving psychiatric treatment
can be included if mutual agreement is achieved with their
current care-giver. Patients will also be excluded if they are
involved in legislative procedures for unemployment
compensation. (See Figure 1 for a flowchart of the partic-
ipants.)
Intervention
Training
All OPs will receive training in the diagnosis and treat-
ment of common mental disorder in three sessions. They
will be trained in the use of tools for screening and diag-
nostics, and cognitive-behavioural and reattribution tech-
niques. The psychiatrists will be trained to make a
diagnosis, and a treatment plan, and to formulate sugges-
tions aimed at RTW specifically tailored to the patient's
mental disorder. The psychiatrists will see the patient once
and make a written report to the OP by consultation letter.
A psychiatrist and an OP from the research group will pro-
vide the training.
Treatment in the intervention group
The care provided in the intervention group will follow a
collaborative care approach: patient-tailored care exe-
cuted within a team of the OP, the patient, the consulting
psychiatrist, and in some cases the General Practitioner
(GP). According to a previously developed method[20], a
treatment plan will be formulated by the consultant psy-
chiatrist, together with the patient. This will be specifically
tailored to the diagnosed common mental disorder, with
a focus on RTW. The OP will be informed about the treat-
ment recommended by the consultant psychiatrist. Subse-
quently, the OP will co-ordinate the care and evaluate the
treatment steps. During the consultation, the psychiatristBMC Health Services Research 2007, 7:29 http://www.biomedcentral.com/1472-6963/7/29
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will make an inventory of treatment that has been offered
to the patient before, and will decide, together with the
patient, whether more intensive treatment is needed. This
depends on the severity of symptoms, the perceived well-
being of the patient, and on the level of general function-
ing according to the GAF score on Axis V of the DSM-
IV[38] a method that has been described elsewhere[39].
Treatment in the control group
Half of the OPs will be randomized to the control group,
and their patients will receive CAU. The actual content of
the CAU (e.g. medication, number of contacts with OP,
GPs and specialists) will be assessed according to the Scale
for Medical Utilisation of Health Services[40].
Flowchart of patients Figure 1
Flowchart of patients.
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Outcome parameters
1. Primary outcome measure
The primary outcome measure will be the level of func-
tioning, as assessed with the SF-20[41-43].
2. Secondary outcome measures
The severity of the symptoms will be measured with the
PHQ[35] and the SCL-90[44]. Quality of life will be
assessed with the EQ-5D[45,46] and the SF-20, both of
which are validated tools for the assessment of general
health-related quality of life.
In addition to the evaluation of improvement in general
functioning, an attempt will also be made to assess the
cost-utility of psychiatric consultation compared to CAU.
Therefore, an estimate will be made of the direct medical
costs and productivity costs. The necessary data collected
by means of the Trimbos/iMTA questionnaire for Costs
associated with Psychiatric Illness (TiC-P)[47,48].
Additional outcome measures will be the MVI-20, a ques-
tionnaire assessing fatigue[49] and the ALCOS-12 that
assesses general competence, resilience and initiative in
an employee[50].
Process measures will be satisfaction of the employee with
the OP (VAS) and compliance with the advice given by the
consultant psychiatrist.
Baseline measurements will take place before inclusion
(T0), and follow up measurements will take place at 3
months with the TiC-P and EQ-5D (T1) and at 6 months
(T2).
Sample size
In the present study, there will be cluster randomization
among the OPs, and Multi Level Analysis (MLA) will be
performed with OPs at the first hierarchical level and
patients at the second level. The SF-20 will be the primary
outcome measure for the power calculation, which will be
based on the design effect. This is the factor needed to
enlarge the total sample size that would be reached the
same standard error that would be reached using rand-
omization between patients and a General Linear Model
(GLM) analysis in the sample. The formula is[51]: Design
effect = 1+(n-1)ρ1
n = the mean sample size at the second hierarchical level
(patient level in this instance) and ρ1 = the intra-class cor-
relation
If a GLM with repeated measures would be used in a study
with randomization among patients, with a variance of
1.0, then a sample size of 2 × 10 would be needed for a
power of 0.90. A variance of 1.0 as intraclass correlation
would be acceptable as a presumption if the contrast
between the two groups would be rather high, i.e. if the
CAU that was provided was different to the consultation
intervention provided in the different practices. We pre-
sume that this is the case, because psychiatric consultation
in addition to OP care, as in the present study, is a new
method for the Netherlands that differs substantially from
normal standards of care [20]. Under these assumptions,
in a MLA study such as this one, with an SD of 1.0, and a
mean number of 3 patients per OP, this would result in a
design effect of 3, implying that N should be multiplied
by 3, compared to the number needed for a power of 0.90
in patient-randomised GLM analysis. If in such a study a
standardized difference of 1.0 was detected, a sample size
of 2 × 30 completers would be needed in order to detect a
clinically relevant significant improvement of 25%, com-
pared to the spontaneous recovery in the control group on
the SF-20. This is the sample size that we aim to achieve in
this study[52,53].
Analysis
Intention-to-treat analysis will be performed by means of
MLA, with OPs in the primary hierarchical level. Subse-
quently, at the secondary hierarchical level, patient char-
acteristics influencing the outcome will be analysed. If
differences in outcome are found in MLA, the effect size
will be estimated by Chi-square analysis and described in
Cohen's d[54]. To control for possible skew ness in the
randomized groups, as far as the distribution of con-
founders is concerned, propensity scores will be calcu-
lated[55]. Possible confounders, such as age, gender,
history of mental disorder, history of treatment, fatigue,
resilience, and satisfaction and compliance of the
employee, will be entered as variables in the analysis.
Time-frame of the study
The preparatory period will be 6 months. Subsequent to
the approval of the Medical Ethics Committee, the OPs
will be recruited and the psychiatrists will be trained. The
inclusion and intervention phase will take 12 months.
The follow-up phase will be 12 months, and data-analyses
will last for 6 months. The total duration of the study will
be 3 years.
Ethical principles
The study has been planned, and will be executed in
accordance with the principles laid down in the Helsinki
declaration (Edinburgh, Scotland amendment, October
2000). Participation in the study will be voluntary, and
written informed consent will be obtained. Patients will
be explicitly informed of the fact that they can withdraw
their consent to participate at any time, without specifica-
tion of reasons and with no negative consequences for
their future medical treatment. Patients who wish to with-
draw from the study will receive CAU. The study has beenBMC Health Services Research 2007, 7:29 http://www.biomedcentral.com/1472-6963/7/29
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approved by the Medical Ethics Committee of the
METiGG, Kamer Zuid protocol 5.127.
Discussion
Strengths and limitations
One limitation of the study might be that the organization
of care in companies could be a hazard, because this sec-
tor is under pressure to work more and more efficiently. It
might also be difficult to establish regular contact between
OPs, consultant psychiatrists and GPs, because OPs gener-
ally work supraregionally. Specific attention will be paid
to limitations in implementation due to regional differ-
ences.
A strength of the study might be that early consultation
could be very helpful to enhance early RTW, and thus
might also improve recovery from a mental disorder. By
embedding the psychiatric consultation in the company
care setting, timely access to specialist care will be
improved and discontinuity of care will be avoided.
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